<DOC>
	<DOC>NCT02078310</DOC>
	<brief_summary>A Phase 1b/2, Randomized, Double-blind, Placebo-Controlled, Multiple Oral Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients with Dementia</brief_summary>
	<brief_title>Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>Part 1 Healthy geriatric volunteers MMSE score of &gt;= 26 at screening BMI between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening Part 2 Geriatric patients with a clinical diagnosis of dementia MMSE score of &lt; 26 at screening BMI between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening Any clinically significant illness within 6 months before screening Any history of cancer within last 5 years History of Hepatitis B or C infection and elevated ALT, AST or bilirubin above the upper limit of normal level Any subject considered to be an imminent danger to themselves or others</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Dementia,</keyword>
	<keyword>Healthy</keyword>
	<keyword>geriatric</keyword>
	<keyword>volunteers</keyword>
	<keyword>patients</keyword>
</DOC>